Psoriatic Arthritis
📧 Sign up to get email alerts when something new happens for Psoriatic Arthritis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-10-08EMA Authorised: Humira (adalimumab) — AbbVie Deutschland GmbH & Co. KG
The EMA authorised Humira (adalimumab) by AbbVie Deutschland GmbH & Co. KG for multiple indications including ankylosing spondylitis, juveni…
-
FDA approval · 2025-09-17FDA Approved: AMJEVITA — Supplemental Application (Nuvaila Limited)
The FDA approved a supplemental BLA for AMJEVITA (adalimumab-atto) submitted by Nuvaila Limited. The action concerns regulatory approval rel…
-
FDA approval · 2025-09-03FDA Approved: INFLECTRA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for Inflectra (infliximab-dyyb) from Pfizer to update its labeling and/or indications, following…
-
FDA approval · 2025-08-14FDA Approved: OTULFI — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for OTULFI (ustekinumab-AAUZ) from Fresenius Kabi USA, LLC.
-
EMA approval · 2025-08-13EMA Authorised: Enbrel (etanercept) — Pfizer Europe MA EEIG
The European Medicines Agency authorised Enbrel (etanercept) for multiple inflammatory diseases including rheumatoid arthritis, ankylosing s…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-07-29FDA Approved: ADALIMUMAB — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for Sandoz Inc for the adalimumab biosimilar ADALIMUMAB-ADAZ, enabling its use with indications cons…
-
EMA approval · 2025-07-17EMA Authorised: Nordimet (methotrexate) — Nordic Group B.V.
EMA authorised Nordimet (methotrexate) by Nordic Group B.V. for use in arthritis-related conditions including rheumatoid arthritis, psoriati…
-
EMA approval · 2025-06-24EMA Authorised: Zessly (infliximab) — Sandoz GmbH
EMA authorised Zessly (infliximab) from Sandoz GmbH as a biosimilar for treatment of several inflammatory diseases, including rheumatoid art…
-
FDA approval · 2025-05-22FDA Approved: STARJEMZA — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approved STARJEMZA (ustekinumab-hmny) from Hikma Pharmaceuticals USA Inc. as a biosimilar to ustekinumab, enabling marketing for the sam…
-
EMA approval · 2025-05-19EMA Authorised: Orencia (abatacept) — Bristol-Myers Squibb Pharma EEIG
The EMA authorised Orencia (abatacept) by Bristol-Myers Squibb Pharma EEIG for rheumatoid arthritis, psoriatic arthritis, and juvenile idiop…
-
FDA approval · 2025-04-30FDA Approved: USTEKINUMAB-TTWE — Original Application (Quallent Pharmaceuticals Health LLC)
FDA approves an original biologics license application for USTEKINUMAB-TTWE from Quallent Pharmaceuticals Health LLC.
-
FDA approval · 2025-04-30FDA Approved: SELARSDI — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for SELARSDI (ustekinumab-aekn) from Teva Pharmaceuticals USA, Inc., representing an approval of a b…
-
FDA approval · 2025-04-30FDA Approved: OTULFI — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for OTULFI (ustekinumab-aauz) from Fresenius Kabi USA, LLC.
-
FDA approval · 2025-04-30FDA Approved: STEQEYMA — Original Application (CELLTRION USA, Inc.)
The FDA approved STEQEYMA (ustekinumab-stba) from Celltrion USA, Inc. under an Original Biologics License Application.
-
FDA approval · 2025-04-30FDA Approved: YESINTEK — Original Application (Biocon Biologics Inc.)
The FDA approved Yesintek (ustekinumab) from Biocon Biologics Inc. under an original Biologics License Application. It is indicated for plaq…
-
FDA approval · 2025-04-30FDA Approved: OTULFI — Original Application (Fresenius Kabi USA, LLC)
OTULFI (USTEKINUMAB-AAUZ) received FDA approval under an Original Application from Fresenius Kabi USA, LLC.
-
FDA approval · 2025-04-28FDA Approved: STEQEYMA — Supplemental Application (CELLTRION USA, Inc.)
The FDA approved a supplemental application for STEQEYMA (ustekinumab-stba) from Celltrion USA, Inc.
-
FDA approval · 2025-04-14FDA Approved: OTULFI — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental Biologics License Application for OTULFI (ustekinumab-AAUZ) from Fresenius Kabi USA, LLC.
-
FDA approval · 2025-04-07FDA Approved: ADALIMUMAB — Supplemental Application (CELLTRION USA, Inc.)
FDA approved a supplemental application for ADALIMUMAB-AATY, a biosimilar adalimumab from Celltrion USA, Inc., in connection with its regula…
-
FDA approval · 2025-04-01FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ustekinumab (Stelara) by Janssen Biotech, Inc.
-
FDA approval · 2025-03-26FDA Approved: RINVOQ — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for Rinvoq (upadacitinib) from AbbVie, resulting in labeling changes to the product.
-
FDA approval · 2025-03-13FDA Approved: USTEKINUMAB-TTWE — Supplemental Application (Quallent Pharmaceuticals Health LLC)
The FDA approved a supplemental application for USTEKINUMAB-TTWE from Quallent Pharmaceuticals Health LLC, updating the product’s labeling a…
-
EMA approval · 2025-03-03EMA Authorised: Nepexto (etanercept) — Biosimilar Collaborations Ireland Limited
EMA authorised Nepexto, a biosimilar of etanercept, developed by Biosimilar Collaborations Ireland Limited, for several inflammatory arthrit…
-
FDA approval · 2025-02-26FDA Approved: CELECOXIB — Supplemental Application (Apotex Corp.)
FDA approved Apotex Corp.'s supplemental application for Celecoxib (celecoxib), authorizing a generic version under the ANDA pathway. The ac…
-
FDA approval · 2025-02-21FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XELJANZ XR (tofacitinib) submitted by Pfizer, updating the extended-release formulation's label.